Antibiotic Resistance in Dermatology

Antibiotic Resistance in Dermatology

Antibiotic Resistance in Dermatology

On this page

Resistance 101 - Bugs Fight Back

  • Antibiotic resistance: Microbes evolve mechanisms to nullify drug effects, leading to treatment failure.
  • Core Mechanisms:
    • Enzymatic Inactivation: e.g., β-lactamases hydrolyze β-lactam rings (penicillins, cephalosporins).
    • Target Site Modification: e.g., mecA gene alters Penicillin-Binding Protein (PBP2a) in MRSA; ribosomal RNA methylation (macrolides, clindamycin).
    • Reduced Permeability / ↓ Influx: Porin channel loss or modification limits drug entry.
    • Active Efflux Pumps: Membrane proteins actively expel antibiotics (e.g., tetracyclines, fluoroquinolones, macrolides).
    • Biofilm Formation: Protective polysaccharide matrix shields bacteria, reduces drug penetration. Mechanisms of Antibiotic Resistance in Bacteria
  • Genetic Basis:
    • Spontaneous chromosomal mutations.
    • Horizontal Gene Transfer (HGT): Acquisition of resistance genes via:
      • Plasmids (e.g., R-factors)
      • Transposons ("jumping genes")
      • Bacteriophages (transduction)

⭐ The mecA gene, encoding PBP2a for methicillin resistance in Staphylococcus aureus (MRSA), is located on a mobile genetic element called Staphylococcal Cassette Chromosome mec (SCCmec).

Key resistant bacteria in dermatology:

SuperbugResistance HighlightsKey Skin Manifestations
MRSA (Methicillin-Resistant S. aureus)mecA gene (altered PBP2a), PVL toxin in CA-MRSAAbscesses, furuncles, cellulitis, impetigo
VISA/VRSA (S. aureus)Thickened cell wall, vanA gene clusterSevere, refractory MRSA-like infections
MDR-Pseudomonas aeruginosaEfflux pumps, ESBLs, MBLs, AmpC β-lactamasesEcthyma gangrenosum, burn wound infections, green nail syndrome
ESBL-Enterobacterales (e.g., E. coli, Klebsiella)CTX-M enzymes commonSurgical site infections, diabetic foot ulcers, cellulitis

⭐ The D-test is crucial for detecting inducible clindamycin resistance in erythromycin-resistant Staphylococcus aureus. A positive D-test (flattening of the clindamycin inhibition zone) predicts clindamycin treatment failure.

📌 Remember common resistance patterns to guide empirical therapy choice before culture results.

Resistance Drivers - Fueling the Fire

  • Antibiotic Misuse & Overuse:
    • Overuse of broad-spectrum antibiotics.
    • Incomplete antibiotic courses by patients.
    • Self-medication, Over-The-Counter (OTC) availability (India).
    • Use for viral/non-bacterial illness.
  • Healthcare & Systemic Factors:
    • Poor antibiotic stewardship.
    • Lax Infection Prevention & Control (IPC) in healthcare.
    • Lack of rapid diagnostics.
  • Patient-Related Factors:
    • Poor patient adherence.
    • Patient demand for antibiotics.
  • Dermatology-Specific Drivers:
    • Misuse of topical antibiotic-steroid Fixed Dose Combinations (FDCs).
    • Prolonged/unsupervised topical antibiotic use.

    ⭐ Methicillin resistance in Staphylococcus aureus (MRSA) is primarily due to the mecA gene, encoding Penicillin-Binding Protein 2a (PBP2a).

  • Microbial Adaptation Mechanisms:
    • Genetic mutations, horizontal gene transfer (e.g., plasmids, transposons).
    • Biofilm formation facilitating persistence & resistance.

Combat Strategy - Tackling Tough Bugs

  • Identify & Confirm Resistance:
    • Clinical suspicion: non-responsive or recurrent infections.
    • 💡 Crucial: Culture & Sensitivity (C&S) testing.
    • Molecular diagnostics (e.g., PCR for mecA gene in MRSA).
  • Treatment Principles:
    • Guided by C&S: targeted therapy.
    • Surgical drainage of abscesses/collections.
    • De-escalate from empirical to narrow-spectrum.
    • Combination therapy for severe/polymicrobial infections.
  • Antibiotic Stewardship (ASP): 📌
    • Optimize selection, dose, duration.
    • Restrict empirical broad-spectrum antibiotics.
    • Patient education: complete course, no sharing.
    • Implement infection control measures.
  • Key Pathogens & Options (India Focus):
    • MRSA: Vancomycin, Linezolid, Teicoplanin, Clindamycin (D-test negative).
    • MDR Gram-negatives (e.g., Pseudomonas, Acinetobacter).

Antibiotic susceptibility testing

⭐ D-test is mandatory before prescribing Clindamycin for suspected Staphylococcal infections if erythromycin resistance is present, to detect inducible clindamycin resistance (iMLSB).

High‑Yield Points - ⚡ Biggest Takeaways

  • MRSA is a critical concern in skin infections; be aware of community (CA-MRSA) and hospital-acquired (HA-MRSA) strains.
  • Overuse and misuse of topical antibiotics (e.g., mupirocin, fusidic acid) significantly drive resistance.
  • Key resistant pathogens: MRSA, Pseudomonas aeruginosa, and increasingly, beta-hemolytic streptococci.
  • Base empirical therapy on local antibiograms; avoid broad-spectrum antibiotics unnecessarily.
  • Promote antibiotic stewardship: use appropriate drug, dose, and duration; consider shorter courses and de-escalation where possible.
  • Emergence of MDR (Multidrug-Resistant) organisms poses a growing therapeutic challenge in dermatology practice in India.

Practice Questions: Antibiotic Resistance in Dermatology

Test your understanding with these related questions

A peculiar organism has resistance to azithromycin, but is sensitive to ticarcillin, clavulanic acid, cotrimoxazole. Identify the organism?

1 of 5

Flashcards: Antibiotic Resistance in Dermatology

1/10

Scrofuloderma is a _____bacillary type of cutaneous tuberculosis

TAP TO REVEAL ANSWER

Scrofuloderma is a _____bacillary type of cutaneous tuberculosis

multi

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial